mobile-banner

Meet Jeff, a patient with newly diagnosed BRCA2 m mCSPC

joseph-image

Not an actual patient.

Meet Jeff, a patient with newly diagnosed BRCA2 m mCSPC

Age: 58

Medical history:

Presented with stabbing sensation in the pelvis that worsened with movement, limiting his daily activities for the past 2 to 3 weeks.

  • History of high blood pressure, currently managed on an ARB and CCB
  • Family history of BRCAm breast cancer and prostate cancer

Current labs/imaging:

BRCA2 mutation

  • PSA of 7.8 ng/mL
  • Gleason score: 7
  • ECOG PS 1
  • PSMA PET results indicate metastases in the pelvic and para-aortic lymph nodes as well as bone metastases in the spine, pelvis, and ribs

NCCN Guidelines, and AUA Guidelines recommend germline testing for patients like Jeff with1,2:

  • Family history of BRCAm cancers
  • Current metastases
  • High-risk status

Germline testing indicated BRCA2 m positivity and Jeff was diagnosed with BRCA2 m mCSPC

Treatment was initiated with AKEEGA®, the first targeted treatment for BRCA2 m mCSPC3

  • Jeff was able to remain on treatment due to the manageable safety profile of AKEEGA®3
  • Convenient once-daily dosing meant that Jeff didn't have to remember a complex dosing schedule3

ARB, angiotensin receptor blocker; AUA, American Urological Association; BRCA2 m, BRCA2 gene-mutated; BRCAm, BRCA gene-mutated; CCB, calcium channel blocker; ECOG, Eastern Cooperative Oncology Group; mCSPC, metastatic castration-sensitive prostate cancer; NCCN, National Comprehensive Cancer Network; PET, positron emission tomography; PS, performance status; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen.

References:

  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.4.2026. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed December 18, 2025. To view the most recent and complete version of the guideline, go to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  2. Lowrance W, Dreicer R, Jarrard DF, et al. Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023). J Urol. 2023;209(6):1082-1090.
  3. AKEEGA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.